Download Problem / Opportunity

The Global Leader in
Genetic Science for Eye Care
DNA Testing for Eye Care
The Problem Today
Full DNA sequencing is too costly, has a slow turn-around, delivers too
much data, and lacks accuracy
The Avellino Solution Available Today
Targeted DNA Testing for Eye Care
– Simple, cheek swab
– Rapid, 24-48 hours
– Affordable
– Accurate, no false positives or negatives
– Actionable, “go/no-go” surgery decision
Our Growth Strategy
Build on our DNA Test Platform Business
Gene Therapy
$11B in 2025,
CAGR 48.9%
Pharmacogenomics
Diagnostic
Testing
Global Genomics Market–$17B in
2020
2015
Large Market Opportunities
Exist for our Technology in Eye Care
Glaucoma
60 M worldwide
3 M United States
Cataract
20-30 M worldwide
3 M US
LASIK
2-3 M worldwide
350,000 United States
2015
Retina - AMD
150-200 M worldwide
2-5 M United States
Avellino DNA Test Development Roadmap
Moving over time from the front to the back of the eye
Refractive
Corneal Dystrophy
Keratoconus
EBMD
Our
market
today
Glaucoma
Pharmacotherapy
Active
R&D
Back of the
Eye Ideas on
the Drawing
Board
Cataract
Corneal Dystrophy
Keratoconus
EBMD
Active
R&D
Retina
Retinits Pigmentosa
Macular Degeneration
Avellino Labs Technology Advantage
Int’l Patent
Protection
4 Granted,
3
Pending/Provisional
Clinical Data
Half Million and
Counting
Global Lab
Network
9 Labs Worldwide
CLIA Certified in US
Standard of Care
Japan and South
Korea
500+ Protected
Collaborative
R&D
California, South
Korea & China
Intellectual Property Portfolio
US and International Patents Issued
1. System For Diagnosis Of Avellino Corneal Dystrophy
1. Method For Requesting And Checking Results Of Diagnostic Tests For Avellino
Corneal Dystrophy
1. Primer For Detecting Avellino Corneal Dystrophy
1. Multi-Spot Metal-Capped Nanostructure Array Nucleic Acid Chip For Diagnosis Of
Corneal Dystrophy And Preparing Method Thereof
US and International Pending Patents
1. Methods For Improved Isolation Of Genomic DNA Templates For Allele Detection
Pct/Us14/29466
2. Methods For Multiplex Detection Of Alleles Associated With Ophthalmic Conditions
Pct/Us14/65975
3. Gene Therapy – Methods for the Treatment of Corneal Dystrophies US Provisional
62/242,204
Competition
• Unique Positioning
– The only company dedicated to Genetic Science in Eye Care
• Competitive Strategy
–
–
–
–
Exclusive focus on the ophthalmic market
Rapid first-to-market products
Invest in IP to erect high barriers to entry
24/7 rapid research via global lab collaboration to stay ahead
• Competitive Landscape
– Larger players are focused on large opportunities outside eye
care
• i.e. Breast Cancer & Alzheimer's
Management Team
Gene Lee, Chairman and Founder
•
•
•
Started Avellino Labs in 2008 in South Korea
Serial Entrepreneur
20 years in Pharma & Healthcare
Peter Falzon, CEO
•
•
•
Joined Avellino Labs in 2015
Public & Private Company CEO
Experience
25 years in the Eye Care Industry
Scott Korney, COO
•
•
•
Established Avellino Lab USA in 2012
Entrepreneur and Founder Experience
30 years in the Bio-Science Industry
Scientific Advisory Board
Anthony J. Aldave, MD
UCLA, Jules Stein Eye Institute
Chief of the Cornea and Uveitis Division
Sonia Yoo, MD
University of Miami, Bascom Palmer Eye Institute
Professor of Ophthalmology and Chief of LASIK Services
Ed Manche, MD
Stanford University, Byers Stein Eye Institute
Chief of Cornea and Refractive Surgery
Janey Wiggs, MD, PhD
Harvard University, Massachusetts Eye and Ear Infirmary
Associate Director, Ocular Genomics Institute
Terry Kim, MD
Duke University Eye Center
Chief of Cornea and External Disease Services
International Medical Advisory Board
Anthony J. Aldave, MD
UCLA, United States
John Marshall PhD
King’s College, UK
Zhang Fenju, MD
Beijing Tongren Hosp, China
Wang Qinmei, MD
Wenzhou Univ, China
Burkhard Dick, MD
Bochum University, Germany
Zhou Xingtao, MD
Fudan Univ, China
Francesco Carones, MD
Private Practice, Italy
Proprietary and Confidential
Company Milestones